Research programme: antisense obesity therapies - Isis Pharmaceuticals

Drug Profile

Research programme: antisense obesity therapies - Isis Pharmaceuticals

Alternative Names: JNK1 antisense inhibitors; mDIC antisense inhibitors

Latest Information Update: 11 Feb 2011

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Dicarboxylic-acid transporter inhibitors; Genetic transcription inhibitors; Mitogen-activated protein kinase 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 03 Jul 2007 Preclinical trials in Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top